Orion Corporation is holding its Annual General Meeting today, March 31, 2011, at 2.00 p.m. EEST. President and CEO Timo Lappalainen will present a review of Orion's year 2010. In his presentation Mr. Lappalainen will mention that Orion's sales have developed well in early 2011, which indicates a strong result for Q1 2011.
The complete agenda of the AGM was published on March 9, 2011, and it is available on the company website at www.orion.fi. The materials of the review of the President and CEO Timo Lappalainen are available on the company website latest on the following day.
The decisions of the AGM will be communicated in a stock exchange release later today, after the meeting.
Orion will publish the Interim Report January-March 2011 on Wednesday, 27 April 2011.
|Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Orionintie 1A, FI-02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.